MX2023003476A - Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados. - Google Patents

Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados.

Info

Publication number
MX2023003476A
MX2023003476A MX2023003476A MX2023003476A MX2023003476A MX 2023003476 A MX2023003476 A MX 2023003476A MX 2023003476 A MX2023003476 A MX 2023003476A MX 2023003476 A MX2023003476 A MX 2023003476A MX 2023003476 A MX2023003476 A MX 2023003476A
Authority
MX
Mexico
Prior art keywords
sup
mrgpr
methods
mas
modulators
Prior art date
Application number
MX2023003476A
Other languages
English (en)
Spanish (es)
Inventor
Esther Martinborough
Liming Huang
Marion Lanier
Adam Yeager
Brandon Selfridge
Marcos Sainz
Marcus Boehm
Original Assignee
Escient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escient Pharmaceuticals Inc filed Critical Escient Pharmaceuticals Inc
Publication of MX2023003476A publication Critical patent/MX2023003476A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2023003476A 2020-09-25 2021-09-24 Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados. MX2023003476A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063083638P 2020-09-25 2020-09-25
US202163145407P 2021-02-03 2021-02-03
US202163211987P 2021-06-17 2021-06-17
PCT/US2021/052044 WO2022067094A1 (en) 2020-09-25 2021-09-24 Modulators of mas-related g-protein receptor x2 and related products and methods

Publications (1)

Publication Number Publication Date
MX2023003476A true MX2023003476A (es) 2023-06-22

Family

ID=78302949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003476A MX2023003476A (es) 2020-09-25 2021-09-24 Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados.

Country Status (11)

Country Link
US (2) US11919864B2 (https=)
EP (1) EP4217345A1 (https=)
JP (1) JP2023542541A (https=)
KR (1) KR20230097015A (https=)
CN (1) CN116406357A (https=)
AU (1) AU2021347360A1 (https=)
CA (1) CA3193207A1 (https=)
IL (1) IL301575A (https=)
MX (1) MX2023003476A (https=)
WO (1) WO2022067094A1 (https=)
ZA (1) ZA202304729B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023003476A (es) * 2020-09-25 2023-06-22 Escient Pharmaceuticals Inc Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados.
US11970452B2 (en) * 2020-10-21 2024-04-30 Escient Pharmaceuticals, Inc. Modulators of mas-related G-protein receptor X2 and related products and methods
CR20240463A (es) 2022-03-30 2025-02-05 Escient Pharmaceuticals Inc Derivados de quinolina como moduladores del receptor x2 de la proteína g relacionados con mas y productos relacionados
CN115850250B (zh) * 2022-10-25 2025-12-23 南京师范大学 一种可控可视化的一氧化碳释放剂及其制备方法和应用
CN121532382A (zh) * 2023-07-13 2026-02-13 北京普祺医药科技股份有限公司 Mas相关g蛋白受体x2的拮抗剂及其用途
WO2025042736A1 (en) 2023-08-18 2025-02-27 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
CN119504738A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为mrgprx2拮抗剂的化合物及其制备方法和应用
WO2025119372A2 (zh) * 2023-12-08 2025-06-12 武汉人福创新药物研发中心有限公司 Mrgprx2拮抗剂及用途
WO2025153014A1 (zh) * 2024-01-17 2025-07-24 武汉人福创新药物研发中心有限公司 Mas相关g蛋白受体x2拮抗剂及用途
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
WO2025223036A1 (zh) * 2024-04-23 2025-10-30 凯复(苏州)生物医药有限公司 Mrgprx2拮抗剂、包含其的药物组合物及其用途
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
JP2026009006A (ja) * 2024-07-01 2026-01-19 日本たばこ産業株式会社 ピリダジノン化合物及びその医薬用途
WO2026037254A1 (zh) * 2024-08-10 2026-02-19 杭州英创医药科技有限公司 作为mrgprx2拮抗剂的化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1509184A (zh) * 2001-03-19 2004-06-30 �ձ���ҩ��ʽ���� 止痒剂
AU2002331621B2 (en) * 2001-08-15 2008-06-05 Icos Corporation 2H-phthalazin-1-ones and methods for use thereof
WO2004078114A2 (en) * 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
EP1706384A1 (en) * 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
JP2006124387A (ja) * 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
CN102625799A (zh) * 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
PH12014500888A1 (en) * 2011-11-08 2014-06-09 Arena Pharm Inc Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
WO2014120995A2 (en) * 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
MX2023003476A (es) * 2020-09-25 2023-06-22 Escient Pharmaceuticals Inc Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados.

Also Published As

Publication number Publication date
EP4217345A1 (en) 2023-08-02
IL301575A (en) 2023-05-01
JP2023542541A (ja) 2023-10-10
US20230065217A1 (en) 2023-03-02
AU2021347360A9 (en) 2024-02-08
US12275707B2 (en) 2025-04-15
WO2022067094A1 (en) 2022-03-31
KR20230097015A (ko) 2023-06-30
US20240336570A1 (en) 2024-10-10
ZA202304729B (en) 2025-10-29
AU2021347360A1 (en) 2023-05-25
CN116406357A (zh) 2023-07-07
CA3193207A1 (en) 2022-03-31
US11919864B2 (en) 2024-03-05

Similar Documents

Publication Publication Date Title
MX2023003476A (es) Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados.
MX2021011647A (es) Moduladores del receptor x4 de proteina g relacionado con mas y productos y metodos relacionados.
WO2022061008A3 (en) Modulators of mas-related g-protein receptor x4 and related products and methods
MX2024013914A (es) Moduladores del inflamasoma nlrp3 y productos y metodos relacionados
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
PH12023550130A1 (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same
MX2024011933A (es) Derivados de quinolina como moduladores del receptor x2 de la proteina g relacionado con mas y productos relacionados
PT2038290E (pt) Moduladores de receptor do tipo toll 7
MX2023006047A (es) Degradadores selectivos del receptor de estrogeno.
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
EP4574210A3 (en) Kappa opioid receptor antagonists and products and methods related thereto
MX2022011712A (es) Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados.
BR0314126A (pt) Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
MX2022006470A (es) Tiromimeticos novedosos.
UA102681C2 (ru) Тризамещенные 1,2, 4-триазолы как модуляторы никотиновых ацетилхолиновых рецепторов
ZA202400988B (en) Aak1 inhibitor and use thereof
BR112022003562A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos
MX2023012971A (es) Agonistas del receptor de orexina y sus usos.
MX2020002436A (es) Antagonistas del receptor de vasopresina y productos y metodos relacionados a los mismos.
PH12022552561A1 (en) Gip receptor agonist peptide compounds and uses thereof
CR20220141A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4